Centessa Pharmaceuticals plc (LON:0ACX)

Market Cap	2.43B
Revenue (ttm)	10.95M
Net Income (ttm)	-168.15M
Shares Out	n/a
EPS (ttm)	-1.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	438
Average Volume	302
Open	23.59
Previous Close	22.90
Day's Range	23.41 - 23.80
52-Week Range	9.86 - 24.43
Beta	n/a
RSI	60.87
Earnings Date	Nov 12, 2025

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatme...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2020
• Employees: 77
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ACX

Financial Performance

Financial numbers in USD